KV agrees to FDA plan for resuming work

KV Pharmaceuticals said it has entered a consent decree with the FDA that provides for KV's return to manufacturing and distribution of its products, provided it satisfies a series of requirements. As you know, KV stopped making products in January and cut its workforce in half last month. Release

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.